ISDS Case Map
medicines
Healthcare watchers are calling on India to resist RCEP
Access to health products is non-negotiable; the Indian Government should reject the bullying tactics of the US based medical device industry.
RCEP negotiations should not restrict global access to affordable medicines and vaccines
The RCEP has hidden costs for people's lives
RCEP will give multinational corporations unprecedented rights
Switzerland insists on intellectual property commitments beyond TRIPS.
Sanofi Aventis Ukraine LLC, part of Sanofi global pharmaceutical company, seeks to file a claim against Ukraine to the International Investment Arbitration.
The first ever final award on patents in international investment arbitration by ICSID in the case of Eli Lilly v. Canada has effectively cleared the way for raising future disputes by foreign IPR owners against domestic institutions which can result in stronger and robust IP protection regime.
The new regime has been implemented in order to meet Canada’s obligations under the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union
TPP 11 negotiators have agreed to suspend controversial clauses on medicine monopolies and some governments want to renegotiate other clauses, vindicating public interest group concerns
